Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.
about
Responsible Translation of Stem Cell Research: An Assessment of Clinical Trial Registration and Publications.Cell therapy must be regulated as medicine.Ethical and Regulatory Challenges with Autologous Adult Stem Cells: A Comparative Review of International Regulations.Adipose-Derived Stem Cells in Aesthetic Surgery: A Mixed Methods Evaluation of the Current Clinical Trial, Intellectual Property, and Regulatory Landscape.Advances in bone marrow stem cell therapy for retinal dysfunction.Adipose tissue-derived stromal vascular fraction in regenerative medicine: a brief review on biology and translation.Marketing of unproven stem cell-based interventions: A call to action.ClinicalTrials.gov, stem cells and 'pay-to-participate' clinical studies.Implicit hype? Representations of platelet rich plasma in the news mediaThe Stem Cell Hard Sell: Report from a Clinic's Patient Recruitment Seminar.Unproven Stem Cell-Based Interventions: Advancing Policy through Stakeholder Collaboration.The 5th Annual One Mind Summit: Lessons Learned About "Science Informing Brain Health Policies and Practice".Regenerative medicine in India: trends and challenges in innovation and regulation.California cracks down on stem cell cowboys.Mesenchymal Stem Cells: Time to Change the Name!Can harmonized regulation overcome intra-European differences? Insights from a European Phase III stem cell trial.A Comparative Analysis of Attitudes on Communication Toward Stem Cell Research and Regenerative Medicine Between the Public and the Scientific Community.Mesenchymal stem cells injections for knee osteoarthritis: a systematic overview.Leveraging social media in the stem cell sector: exploring Twitter's potential as a vehicle for public information campaigns.'No one here's helping me, what do you do?': addressing patient need for support and advice about stem cell treatments.Wicked policy issues in regenerative medicine and the need to explore new avenues for public engagement.Special focus issue on regenerative medicine in society: interdisciplinary perspectives (part I) - Foreword.The social production of evidence: regenerative medicine and the 21st Century Cures Act.Identity and ownership issues in the regulation of autologous cells.Cell-based therapeutic strategies for multiple sclerosis.Accelerating regenerative medicine: the Japanese experiment in ethics and regulation.The Council of Europe and the prohibition on human germline genome editing.Ethical and Safety Issues of Stem Cell-Based Therapy.The FDA and the US direct-to-consumer marketplace for stem cell interventions: a temporal analysis.Open for business: a comparative study of websites selling autologous stem cells in Australia and Japan.Current and emerging global themes in the bioethics of regenerative medicine: the tangled web of stem cell translation.Fake news portrayals of stem cells and stem cell research.Somatic Mutations and Clonal Hematopoiesis: Unexpected Potential New Drivers of Age-Related Cardiovascular Disease.Regulating the advertising and promotion of stem cell therapies.Exploiting science? A systematic analysis of complementary and alternative medicine clinic websites' marketing of stem cell therapies.Four Food and Drug Administration draft guidance documents and the REGROW Act: a litmus test for future changes in human cell- and tissue-based products regulatory policy in the United States?Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions.Regulation: Rewriting the regenerative rulebook.The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions.Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis.
P2860
Q33659105-47FBB65C-C1AA-4132-B98B-54C46C68BEBBQ37192040-B38B5600-92CB-43D5-8050-0A4A7C8C412EQ38372717-5DA1BCC1-BA35-4BE4-B570-0139AAC56E85Q38737927-00DEC73C-C33A-49B5-8C12-BA72B1648C11Q38804673-8E515A91-05BC-4FD4-BF88-867D4747C89CQ39376213-108BE581-8104-4F00-A231-893F4A7AEE60Q39416083-049225BA-B3CB-459D-9F80-A212B3EC053EQ39443366-5EE625D9-6CC8-49F4-9904-CD45E5319801Q41326201-3ED4B06E-9F8A-49AA-AE54-A42CBB94C4B1Q41916323-100B2424-59FA-41E8-A543-A476F7799A5BQ42332597-B9048B6E-C9CB-408D-848C-E36A57AD7B7CQ42380225-EAAA314D-D24B-4B71-ABA4-BBB4A86773BAQ45874072-6F382BF2-BC6D-4346-907C-1BD2F4E79033Q46868509-E8347643-E47F-42F6-B411-361610407CD9Q47094268-555E6CCD-C719-4E2B-B778-42AD52A32CA5Q47190431-2E4A0EC8-FC6B-475D-AFBA-8CE4A2C3B672Q47553326-1370C9E1-0837-4D25-8881-8A298A094EF0Q47571899-65A4864F-9D4A-42F2-A86A-2235B952611AQ47622747-A0899506-84D6-4440-9207-613740F8976DQ47622771-8B529478-3D85-45AE-8599-7CAD9D74D067Q47624333-03DE5EE7-9A6F-4DF0-A80B-389A8BA6D621Q47660981-4F64406D-383C-441A-99FD-D0BE689B567CQ47667562-C716EC4B-E696-4C5D-9B23-0CAE1B6B2DEDQ47852426-330B1269-037E-414C-B797-89DA7F9D8426Q47885870-E5BCFA1E-BC86-401F-9C5A-78343B163B88Q49613181-B15A2ACF-818F-4DBE-891E-4130F14F37F6Q49988530-5CB4641A-A6D9-45F5-9372-91C75A97F102Q50050571-3D452FCE-5DA9-4989-B386-788225640BCDQ50070329-85A06EC2-B564-4FC8-AF9A-612591376B96Q50073634-1AEE0C99-8858-4622-B27E-19A2502E5F33Q50098711-3C189462-EC0D-4B8E-8DF1-EC915E3C3FCAQ50112862-780B73C6-E844-4448-A860-0D110C9DC3AAQ50115925-AFA7F11E-A533-4F06-AA0B-6E4C7E8279B0Q50122051-192A1375-CE8A-4EC4-897A-A4F3782CDCE0Q51766621-636CFCA2-75C7-432E-8038-AFCF8EB395E0Q52558237-4B7F2749-7BDF-49D9-8248-67625C5BD4EEQ52686004-D1ABB7B1-20A0-4412-92D6-A68983492F9DQ54634860-67B1E82D-2C8D-4529-9976-2723F9F26DF3Q55259610-C54BFDD7-3335-4F55-930F-146220E34B8BQ55379594-B9AAE4E3-999F-479F-9114-E15C24094E3F
P2860
Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.
@en
Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.
@nl
type
label
Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.
@en
Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.
@nl
prefLabel
Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.
@en
Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.
@nl
P1433
P1476
Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.
@en
P2093
Paul Knoepfler
P304
P356
10.1016/J.STEM.2016.06.007
P407
P577
2016-06-29T00:00:00Z